TY  - JOUR
T1  - Performance and Clinical Utility of a Barcelona-Derived MRI Predictive Model for Clinically Significant Prostate Cancer
A1  - J. Smith
A1  - A. Jones
A1  - M. Brown
JF  - Asian Journal of Current Research in Clinical Cancer
JO  - Asian J Curr Res Clin Cancer
SN  - 3062-4444
Y1  - 2023
VL  - 3
IS  - 2
DO  - 10.51847/D4PZD3XmnR
SP  - 61
EP  - 71
N2  - An MRI-based predictive model (MRI-PM) for estimating the likelihood of clinically significant prostate cancer (csPCa) was created and independently validated across institutions in the Barcelona metropolitan region, accompanied by an online risk calculator (RC) that enables users to define their preferred csPCa probability cut-off. The model was derived from a cohort of 1486 men undergoing 3-tesla multiparametric MRI (mpMRI) and subsequent targeted and/or systematic biopsies at a single academic center. External validation was performed in 946 men evaluated with the same imaging and biopsy workflow at two additional academic hospitals. CsPCa was identified in 36.9% of the development cohort and 40.8% of the validation cohort (p = 0.054). Incorporation of the model increased the diagnostic AUC of mpMRI from 0.842 to 0.897 in the development dataset (p < 0.001) and from 0.743 to 0.858 in the validation dataset (p < 0.001). Using a 15% probability threshold would reduce biopsy procedures by 40.1%, with 5.4% of the 36.9% csPCa cases going undetected. For individuals with PI-RADS 
UR  - https://galaxypub.co/article/performance-and-clinical-utility-of-a-barcelona-derived-mri-predictive-model-for-clinically-signific-lci5tpcnlbe9xbe
ER  -